On last trading day Primerica, Inc. (NYSE:PRI) advanced 0.28% to close at $51.00. Its volatility for the week is 2.02% while volatility for the month is 1.73%. PRI’s sales growth for past 5 years was -9.60% and its EPS growth for past 5 years was -12.70%. Primerica, Inc. (NYSE:PRI) monthly performance is -2.78%. On March 23, Primerica, Inc. (NYSE:PRI) was recently recognized by the Atlanta Journal-Constitution as one of the best workplaces in Georgia. Primerica was the highest ranking public company headquartered in Georgia, and it ranked 7th out of 25 companies in the “large companies” category (500+ employees in Georgia) when compared with private companies and non-profit organizations.
iCAD, Inc. (NASDAQ:ICAD) has 8.00% insider ownership while its institutional ownership stands at 45.10%. In last trading activity company’s stock closed at $8.98. On March 20, iCAD, Inc. (NASDAQ:ICAD) announced that researchers will present three E-posters highlighting results of up to four years of follow up with the Xoft Axxent® Electronic Brachytherapy (eBx®) System® in the treatment of non-melanoma skin cancer (NMSC) at The American Academy of Dermatology 73rd Annual Meeting in San Francisco, California.
Finish Line Inc. (NASDAQ:FINL) belongs to Services sector. Its net profit margin is 4.70% and weekly performance is 0.08%. On last trading day company shares ended up $23.94. Finish Line Inc. (NASDAQ:FINL) distance from 50-day simple moving average (SMA50) is -0.03%. Athletic gear retailer Finish Line, Inc. (NASDAQ:FINL) posted fourth-quarter net income attributable to the company of $40.8 million, down from $43.0 million in the comparable quarter last year. Earnings per share attributable to company shareholders were $0.87, same as last year.
Biogen Idec Inc. (NASDAQ:BIIB) shares decreased -0.63% in last trading session and ended the day at $428.93. BIIB Gross Margin is 87.90% and its return on assets is 22.10%. Biogen Idec Inc. (NASDAQ:BIIB) quarterly performance is 27.75%. Biogen Idec Inc. (NASDAQ:BIIB) and AbbVie announced that the European Medicines Agency (EMA) has validated the companies’ Marketing Authorisation Application (MAA) for ZINBRYTA™ (daclizumab high-yield process) for the treatment of relapsing forms of multiple sclerosis (MS) in the European Union (EU). Validation confirms that the submission is complete and signifies the initiation of the review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP).
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) in last trading activity fell -3.26% to close at $4.45. Company weekly performance is -15.08% while its quarterly performance stands at 21.58%. Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) is -21.24% away from its 52 week high.